Scintigraphic study to investigate the effect of food on a HPMC modified release formulation of UK-294,315

Journal of Pharmaceutical Sciences

Volumn 98, Issue 4, 2009, Pages 1568-1576

  Davis, J ^a   Burton, J ^a   Connor, A L ^b   Macrae, R ^a   Wilding, I R ^c  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b PHARMACEUTICAL PROFILES LTD   (United Kingdom)

^c Lan Wilding Associates Ltd   (United Kingdom)

Author keywords

Food effects; Modified release; Pharmacokinetics; Scintigraphy; UK 294,315

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM PHOSPHATE; CROSCARMELLOSE SODIUM; DI SOL; HYDROXYPROPYLMETHYLCELLULOSE; LACTOSE; MAGNESIUM STEARATE; METHYLCELLULOSE; MICROCRYSTALLINE CELLULOSE; POVIDONE; UK 294 315; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DOSAGE FORM; DRUG FORMULATION; DRUG RELEASE; FEEDING; FOOD DRUG INTERACTION; GAMMA SCINTIGRAPHY; HUMAN; HUMAN EXPERIMENT; ISOTOPE LABELING; MALE; MEAL; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STOMACH EMPTYING; TABLET;

EID: 67449116265     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21507     Document Type: Article

References (10)

1. Harrison A, Betts A, Penner K, Beaumont K, Edgington A, Roffey S, Davis J, Comby P, Morgan P. 2002. Nonlinear oral pharmacokinetics of the α-Antagonist 4-Amino-5(4-Fluorophenyl)-6,7- Dimethoxy-2 - [4- (Morpholinocarbonyl) -Perhydr o- l,4-Diazepin-l-YL]Quinoline in Humans: Use of preclinical data to rationalize clinical observations. Drug Metab Dispos 32:197-204.
2. Wilding IR. 2003. What role for scintigraphic imaging techniques and human absorption studies in achieving optimized drug delivery? Drug Deli Syst 18:198.
3. Food and Drug Administration. 2002. Guidance for Industry. Food-Effect Bioavailability and Fed Bio- equivalence Studies. December, http://www.fda.gov/ cder/guidance/5194fnl.pdf.
4. Coupe AJ, Davis SS, Wilding IR. 1991. Variation in gastrointestinal transit of pharmaceutical dosage forms in healthy subjects. Pharm Res 8:360- 364.
5. Davis SS, Hardy JG, Taylor MJ, Whalley DR, Wilson CG. 1984. A comparative study of the gastrointestinal transit of a pellet and tablet formulation. Int J Pharm 21:167-177.
6. Hunt JN, Stubbs DF. 1975. The volume and energy content of meals as determinants of gastric emptying. J Physiol 245:209-225.
7. Davis SS, Hardy JG, Fara JW. 1986. Transit of pharmaceutical dosage forms through the small intestine. Gut 27:886-892.
8. Price JMC, Davis SS, Sparrow RA, Wilding IR. 1993. The effect of meal composition on the gastrocolonic response: implications for drug delivery to the colon. Pharm Res 10:722-726. 9. Richter HM. 1988. Stomach and duodenum. In: Kumar D, Gustavsson S, editors. An illustrated guide to gastrointestinal motility. Chichester: John Wiley, pp 163-174.
9. Hwang S-J, Park H, Park K. 1998. Gastric retentive drug delivery systems. Grit Rev Ther Drug Carrier Syst 15:243-284.
10. Marciani L, Gowland PA, et al. 2001. Assessment of antral grinding of a model solid meal with echoplanar imaging. Am J Physiol 280:G844-G849.